8-K current report · filed Sep 17, 2026

Surgery Partners, Inc. (SGRY) 8-K Current Report: September 17, 2026

Item EX-99.1Item EX-99.2Item 2.01SGRY overview

Short answer

Surgery Partners, Inc. (SGRY) filed an 8-K current report with the SEC on September 17, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.01 (Completion of Acquisition or Disposition of Assets). Completed sale of Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026.

Surgery Partners, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Completed sale of Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026
  • Approximately $796.6 million aggregate consideration, subject to closing cash, indebtedness, expenses and post-closing adjustments
  • Proceeds primarily earmarked for debt repayment, supporting balance-sheet deleveraging
  • Disposition included hospital operations, substantially all related assets and certain liabilities
  • Financial statements and pro forma effects to follow under Item 9.01, important for assessing ongoing revenue and earnings changes

Item EX-99.1 · Exhibit EX-99.1

  • Proposed sale of Mountain View and Idaho Falls hospitals to Intermountain Health for approximately $796.6M
  • Estimated net cash proceeds of $586.5M after $219.7M closing cash and indebtedness and $9.6M working-capital adjustments
  • Pro forma cash rises to $708.8M from $216.7M, while long-term debt declines to $3,331.1M from $3,648.3M
  • Revenue decreases to $1,287.8M for six months ended June 30, 2026 and $2,586.1M for 2025
  • Pro forma net loss attributable to Surgery Partners widens to $69.2M and $108.2M, respectively, versus historical losses of $50.9M and $77.9M

Item EX-99.2 · Exhibit EX-99.2

  • Completed Idaho Falls sale to Intermountain Health for $797M gross and $587M net cash proceeds
  • $1.15B transaction value, implying approximately 7x LTM adjusted EBITDA and 17x average distributions
  • Debt reduction primary proceeds use, with leverage expected to improve 30bps from 4.4x at Q2 2026
  • Portfolio becomes pure-play short-stay surgical, eliminating inpatient pediatrics, obstetrics, neonatology and pharmacy services
  • Updated 2026 guidance: revenue $3.08B-$3.18B and adjusted EBITDA at least $489M; pro forma revenue $2.60B-$2.67B and EBITDA at least $414M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Surgery Partners, Inc. 8-K filings

Get the next SGRY 8-K as it lands

Follow SGRY for push alerts, or ask the research agent what this filing means.